## Johnson & Johnson and Subsidiaries

**Condensed Consolidated Statement of Earnings** 

(Unaudited; in Millions Except Per Share Figures)	FOURTH QUARTER								
	2012			2011			Percent		
			Percent			Percent	Increase		
	A	mount	to Sales	Δ	mount	to Sales	(Decrease)		
Sales to customers	\$	17,558	100.0	\$	16,255	100.0	8.0		
Cost of products sold		6,003	34.2		5,338	32.8	12.5		
Selling, marketing and administrative expenses		5,661	32.2		5,458	33.6	3.7		
Research and development expense		2,331	13.3		2,155	13.3	8.2		
In-process research and development		55	0.3		-	-			
Interest (income) expense, net		89	0.5		148	0.9			
Other (income) expense, net		319	1.8		2,858	17.6			
Restructuring (income) expense, net		-	-		(20)	(0.1)			
Earnings before provision for taxes on income		3,100	17.7		318	1.9	874.8		
Provision for taxes on income		533	3.1		100	0.6	433.0		
Net earnings		2,567	14.6		218	1.3	1,077.5		
Add: Net loss attributable to noncontrolling interest		-	-		-	-			
Net earnings attributable to Johnson & Johnson	\$	2,567	14.6	\$	218	1.3	1,077.5		
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$	0.91		\$	0.08		1,037.5		
Average shares outstanding (Diluted)		2,833.4			2,768.9				
Effective tax rate		17.2 %			31.4 %				
Adjusted earnings before provision for taxes and net earnings attributab	le to J	ohnson & Joh	nnson (1)						
Earnings before provision for taxes on income	\$	4,115	23.4	\$	3,657	22.5	12.5		
Net earnings attributable to Johnson & Johnson	\$	3,376	19.2	\$	3,129	19.2	7.9		
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$	1.19		\$	1.13		5.3		
Effective tax rate	-	18.0 %		-	14.4 %				

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

**Condensed Consolidated Statement of Earnings** 

(Unaudited; in Millions Except Per Share Figures)	TWELVE MONTHS								
		2012	2	2011			Percent		
			Percent			Percent	Increase (Decrease)		
		Amount	to Sales	1	Amount	to Sales			
Sales to customers	\$	67,224	100.0	\$	65,030	100.0	3.4		
Cost of products sold		21,658	32.2		20,360	31.3	6.4		
Selling, marketing and administrative expenses		20,869	31.0		20,969	32.3	(0.5)		
Research and development expense		7,665	11.4		7,548	11.6	1.6		
In-process research and development		1,163	1.7		-	-			
Interest (income) expense, net		468	0.7		480	0.7			
Other (income) expense, net		1,626	2.5		2,743	4.2			
Restructuring (income) expense, net		-	-		569	0.9			
Earnings before provision for taxes on income		13,775	20.5		12,361	19.0	11.4		
Provision for taxes on income		3,261	4.9		2,689	4.1	21.3		
Net earnings		10,514	15.6		9,672	14.9	8.7		
Add: Net loss attributable to noncontrolling interest		339	0.5		-	-			
Net earnings attributable to Johnson & Johnson	\$	10,853	16.1	\$	9,672	14.9	12.2		
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$	3.86		\$	3.49		10.6		
Average shares outstanding (Diluted)		2,812.6			2,775.3				
Effective tax rate		23.7 %			21.8 %				
Adjusted earnings before provision for taxes and net earnings attributab	le to J	ohnson & Joh	inson (1)						
Earnings before provision for taxes on income	\$	18,214	27.1	\$	17,353	26.7	5.0		
Net earnings attributable to Johnson & Johnson	\$	14,345	21.3	\$	13,867	21.3	3.4		
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$	5.10	_	\$	5.00		2.0		
Effective tax rate	•	21.2 %		•	20.1 %		_		

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.